Therapeutics case studies

Clinical trial participation exposes rare disease participants to significant pressure financially, logistically and psychologically, and these incremental pressures can negatively impact a patient’s ability or willingness to enrol or remain in a clinical trial.

In February 2020 ICON quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.

There are no specific pharmaceutical therapies available for TBI. Since 2001, ICON staff have participated in managing mult national TBI trials with several drugs including endopeptidase inhibitor and endothelin converting enzyme inhibitors, involving more than 1,000 TBI patients.

ICON exceeded recruitment objectives within the initial recruitment timelines during COVID-19 pandemic.

A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with ICON to conduct a series of early-phase trials.

ICON partnered with a drug development sponsor to conduct a global programme for Multiple sclerosis (MS) studies in over 2,200 patients.

ICON was engaged to support phase 2 study in patients with heartfailure and impaired systolic function. ICON’s proactive approach ensured the successful delivery of this complex study and enabled the client to make key strategic program decisions to advance their larger phase 2 trial.

The PAC19 VCN digital droplet (dd)PCR test was validated by ICON to detect and monitor CAR-T (chimeric antigen receptor) cell expansion and persistence in patients receiving anti-CD19 CAR-T therapies.

Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.

"A large pharma customer sought expert regulatory support from ICON for a paediatric rare disease development
program."

The sponsor in this case was a large pharmaceutical company that contracted ICON to manage and streamline the training and compliance workload for their phase 2 Alzheimer’s study.

ICON conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation.